Completed PHASE4 INTERVENTIONAL NCT00320632

Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression

Psychopharmacology of Biogenic Amines in Depression

Sponsor: Harvard Medical School (HMS and HSDM)

Interventions Desipramine

Updated 6 times since 2017 Last updated: Aug 17, 2015 Started: Aug 31, 1990 Completion: Jul 31, 1993

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Depression, this trial is completed. The trial is conducted by Harvard Medical School (HMS and HSDM) and has accumulated 6 data snapshots since 1990. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jan 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Aug 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harvard Medical School (HMS and HSDM)
National Institute of Mental Health (NIMH)

Data source: Harvard Medical School (HMS and HSDM)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States